| ICD-116C73 | INTERMITTENT EXPLOSIVE DISORDER (IED)Intermittent explosive disorder |
| ICD-10F63.8 | Other habit and impulse disorders |
| DSM-5-TRF63.81 | Intermittent Explosive Disorder |
1. Definition and nosology
Intermittent Explosive Disorder (IED; ICD-11: 6C73 Intermittent Explosive Disorder; DSM-5-TR: F63.81) — recurrent, uncontrolled verbal or physical aggressive outbursts; disproportionately intense relative to triggering provocation. Remorse or shame after the act.
2. History
- DSM-III (1980) — Official diagnosis of IED.
- DSM-5 (2013) — criteria refined.
- ICD-11 (2019) — under impulse control disorders.
3. Epidemiology
- Lifetime prevalence: 4–7% (Kessler R.C. et al. Arch Gen Psychiatry 2006).
- Sex: higher in males.
- Onset: mid-adolescence.
- Comorbidity: MDD ~70%, anxiety, substance use, BPD, ASPD.
4. Aetiology and pathogenesis
- Heritability 40%.
- Serotonin dysregulation — SSRI effect.
- Trauma and abuse history.
- Disruption of cortex-amygdala regulation.
5. Clinical features
- Recurrent aggression outbursts — verbal (screaming, threat) or physical (object damage, harm to others).
- Explosion out of control — patient unsuccessful in restraining.
- Trigger minimal or minor.
- Post-act remorse, shame, guilt.
- Relationship, work, legal consequences.
6. Diagnosis
6.1 Unified diagnostic criteria
A. One of the following:
- Verbal or physical aggression outbursts, without destructive harm, ≥2 times per week, ≥3 months
- Three or more disruptive/damaging outbursts within a 12-month period.
B. Aggression disproportionate to the trigger.
C. Impulsive (not planned) and not for a specific purpose.
D. Significant distress or functional impairment.
E. Chronological age ≥ 6 years.
F. Not better explained by another mental disorder (manic, ASPD, BPD, conduct disorder); rule out substance effects.
6.2 Source-specific clarifications
- DSM-5-TR — criterion A1 (mild) and A2 (destructive) separately.
- ICD-11 — neither frequency nor age: DSM-5-TR requires the A1/A2 split, twice weekly for three months or three destructive outbursts in 12 months, and age ≥6; ICD-11 sets none of these.
6.3 Diagnostic algorithm
- Clinical interview + family information.
- Scale — OAS (Overt Aggression Scale), BPAQ (Buss-Perry Aggression Questionnaire).
- Comorbidity and exclusion of medical causes (frontal lobe injury, epilepsy, hypoglycemia).
- Toxicology.
6.4 Differential diagnosis
| Condition | Distinguishing feature |
|---|---|
| ASPD (Antisocial) | Planned aggression, no regret. |
| BPD | Emotional lability and relationships central. |
| Manic episode | In the context of an affective episode. |
| Conduct Disorder (6C91) | Multiple instances of antisocial behavior. |
| ODD (6C90) | Persistent oppositional component with aggression, but outbursts are not primary. |
| Frontal lobe pathology | Neurological. |
| Substance-induced aggression | Toxicology. |
7. Examination and assessment
- OAS, BPAQ.
- Medical and neurological.
- Toxicology.
- Comorbidity scales.
8. Treatment
- Fluoxetine (SSRI) — Coccaro E.F. et al. J Clin Psychiatry 2009 RCT — most evidence-based pharmacotherapy in IED; 20–60 mg/day.
- CBT — anger management, cognitive restructuring, behavioral activation, relaxation. McCloskey M.S. et al. J Consult Clin Psychol 2008.
- Mood stabilizers — valproate, lithium (off-label in refractory cases).
- Comorbid disorder treatment.
- Legal coordination when needed.
Source-specific specifications
- Coccaro J Clin Psychiatry 2009 — fluoxetine evidence-based.
- McCloskey 2008 — CBT efficacy.
Treatment methods
- Fluoxetine — SSRI; evidence base from Coccaro RCT in IED.
- CBT for Anger Management — Trigger identification, cognitive restructuring, time-out, relaxation, problem-solving.
- Overt Aggression Scale (OAS) — Aggression Scale.
9. Prognosis
- Significant improvement with fluoxetine and CBT.
- Comorbid ASPD, substance use poor prognosis.
10. Myths and misconceptions
Myth 1: “IED is just ordinary ‘temper tantrum’”
Evidence: Clinical diagnosis based on frequency and functional impairment.
Myth 2: “The patient can stop ‘voluntarily’”
Evidence: impulse control disorder — failure of control is clinical feature; evidence-based treatment (fluoxetine, CBT) required.
Myth 3: “Benzodiazepine calms aggression”
Evidence: benzodiazepine paradoxical disinhibition can occur; contraindicated or used cautiously in IED.
Myth 4: “Only legal punishment is effective”
Evidence: legal punishment alone ineffective; clinical treatment required.
Myth 5: “Antipsychotic is first-line”
Evidence: SSRI first-line; antipsychotic in refractory case.
11. Sources
- WHO. ICD-11. 6C73 Intermittent explosive disorder. 2024.
- APA. DSM-5-TR. 2022.
- Coccaro E.F. et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009;70(5):653–662.
- McCloskey M.S. et al. Cognitive-behavioral therapy for intermittent explosive disorder. J Consult Clin Psychol 2008;76(5):876–886.
- Kessler R.C. et al. The prevalence and correlates of DSM-IV intermittent explosive disorder. Arch Gen Psychiatry 2006;63(6):669–678.